GlassScriptPhysician profile
Ross Pearlman
NPI 1144726555
$7,903.91
in general payments reported to CMS, 2019-2025
23 companies · $4,640 in 2025
The $4,640 reported for 2025 was more than what 94% of Mohs-Micrographic Surgery providers received nationally (typical 2025 total: $462).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $12.27 · 2021: $376 · 2022: $1,616 · 2023: $389 · 2024: $871 · 2025: $4,640.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $3,680 · Food and Beverage: $1,929 · Travel and Lodging: $290.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $3,680.00 |
| Food and Beverage | $1,929.38 |
| Travel and Lodging | $289.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $4,457.43 | 2021-2025 | |
| Lilly USA, LLC | $900.44 | 2022-2025 | Taltz, Ebglyss |
| Abbvie INC. | $612.48 | 2021-2025 | |
| Janssen Biotech, INC. | $321.19 | 2024-2025 | Tremfya |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $228.99 | 2021-2022 | |
| Organogenesis INC. | $207.06 | 2024-2025 | Puraply Wound Matrix, Puraply Am, Cygnus Dual |
| Regeneron Healthcare Solutions, INC. | $140.54 | 2022-2025 | Dupixent |
| Boehringer Ingelheim Pharmaceuticals, INC. | $125.00 | 2023 | Spevigo |
| Merz North America, INC. | $115.66 | 2021 | |
| Incyte Corporation | $87.98 | 2022-2024 | Opzelura |
| E.R. Squibb & Sons, L.L.C. | $83.77 | 2022-2025 | Sotyktu |
| Ucb, INC. | $68.16 | 2024-2025 | Bimzelx |
| Leo Pharma INC. | $59.64 | 2024 | Adbry |
| Pfizer INC. | $49.76 | 2021-2022 | |
| Smith+Nephew, INC. | $48.72 | 2024 | Grafix Pl |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $48.43 | 2022 | |
| Arcutis Biotherapeutics, INC. | $42.08 | 2025 | Zoryve |
| Galderma Laboratories, L.P. | $39.24 | 2025 | Nemluvio |
| Mimedx Group, INC. | $38.63 | 2024 | |
| Dermavant Sciences, INC. | $27.30 | 2024 | Vtama |
| Almirall LLC | $25.93 | 2024 | Klisyri |
| Helsinn Therapeutics (U.S.), INC. | $19.39 | 2021 | |
| Stemline Therapeutics INC. | $17.72 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ross Pearlman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.